(Q38210621)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Epigenetic deregulation in myeloid malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Kristen M Meldi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

24 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

102-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNMT3A Mutations in Acute Myeloid Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Epigenetic modifications and human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

A decade of exploring the cancer epigenome - biological and translational implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Epigenetic vulnerability and the environmental influence on health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Array-based genomic resequencing of human leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Dnmt3a is essential for hematopoietic stem cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Mutation in TET2 in myeloid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

IDH mutation impairs histone demethylation and results in a block to cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

SDH mutations establish a hypermethylator phenotype in paraganglioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Large conserved domains of low DNA methylation maintained by Dnmt3a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Clinical effect of point mutations in myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The Polycomb group protein EZH2 directly controls DNA methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

A polycomb repression signature in metastatic prostate cancer predicts cancer outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Clinical implications of novel mutations in epigenetic modifiers in AML.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Drug effects on nucleic acid modification. I. A specific effect of 5-azacytidine on mammalian transfer RNA methylation invivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

New strategies for relapsed acute myeloid leukemia: fertile ground for translational research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Interaction of MLL amino terminal sequences with menin is required for transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

The long-range interaction landscape of gene promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

Capturing chromosome conformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.04.012

10.1016/J.TRSL.2014.04.012

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813528%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference